Drug delivery from hydrogels

Patent metadata

Field	Value
Publication number	US-11369591-B2
Application number	US-201615152739-A
Country	US
Kind code	B2
Filing date	May 12, 2016
Priority date	May 12, 2015
Publication date	Jun 28, 2022
Grant date	Jun 28, 2022

Abstract

Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

First claim

The invention claimed is:

1. A method of delivering a therapeutic agent to a tissue comprising combining a first precursor and a second precursor that react with each other in presence of a therapeutic agent to form a covalently crosslinked hydrogel in situ in an eye with the therapeutic agent dispersed in the hydrogel, all of the agent being directly disposed in the hydrogel and having a low solubility in water, and with the hydrogel being formed with a spacing between crosslinks that allows diffusion of the agent through the hydrogel, wherein the hydrogel essentially persists at least until the agent has been essentially released.

2. The method of claim 1 with the agent being suspended in the hydrogel.

3. The method of claim 1 wherein the agent is released to provide an effective concentration of the agent in an eye over a period of time.

4. The method of claim 3 wherein the period of time starts after the formation of the hydrogen and ends at 2-36 months.

5. The method of claim 4 wherein, after the period of time, the hydrogel releases a further amount of the agent that is non-toxic.

6. The method of claim 1 wherein the hydrogel is water-degradable, as measurable by the hydrogel being dissolvable in vitro in an excess of water by degradation of water-degradable groups.

7. The method of claim 1 wherein the hydrogel is formed at an intravitreal site.

8. The method of claim 1 wherein the agent is for treatment of a back of the eye disease.

9. The method of claim 8 wherein the back of the eye disease is choroidal neovascularization (CNV), age-related macular degeneration (AMD) cystoid macular edema (CME), diabetic macular edema (DME), posterior uveitis, and diabetic retinopathy, or glaucoma.

10. The method of claim 1 wherein the agent
comprises anti-VEGF,
blocks VEGFR1, blocks VEGFR2, blocks VEGFR3, anti-PDGF, anti-PDGF-R blocks PDGFRβ,
comprises an anti-angiogenic agent, Sunitinib, E7080, Takeda-6d, Tivozanib, Regorafenib, Sorafenib, Pazopanib, Axitinib, Nintedanib, Cediranib, Vatalanib, Motesanib, macrolides, sirolimus, everolimus, a tyrosine kinase inhibitor (TKI), Imatinibn gefinitib, toceranib, Erlotinib, Lapatinib, Nilotinib, Bosutinib Neratinib, lapatinib, Vatalanib,
comprises low-soluble prostaglandin analogues for glaucoma, nepafenac, macrolides, rapamycin, sirolimus, tacrolimus, or
serves to block mTOR receptors for AMD and/or CNV.

11. The method of claim 1 wherein the first precursor and the second precursor are hydrophilic.

12. The method of claim 1 wherein the hydrogel is essentially spherical, essentially discoidal, or essentially cylindroid.

13. The method of claim 11 wherein the first precursor is a multifunctional precursor that comprises a plurality of first functional groups and the second precursor is a multifunctional precursor that comprises a plurality of second functional groups, with the first functional groups and the second functional groups reacting with each other to form covalent bonds for covalently crosslinking the hydrogel.

14. The method of claim 13 wherein the first functional groups comprise electrophilic functional groups and the second functional groups comprise nucleophilic functional groups.

15. The method of claim 14 wherein the first precursor comprises a polyethylene glycol polymer.

16. The method of claim 15 wherein the polyethylene glycol polymer is a branched polymer.

17. The method of claim 16 wherein the first precursor has a number average molecular weight from 5000 to 50,000 Daltons.

18. The method of claim 17 wherein the second precursor comprises a branched polyethylene glycol having 4-16 arms.

19. The method of claim 17 wherein the second precursor is a dilysine, a trilysine, or tetralysine.

20. The method of claim 13 wherein the first multifunctional precursor has arms with a number average molecular weight of about 5000 Daltons each.

21. The method of claim 13 wherein the first precursor and the second precursor are each a four armed branched polyethylene glycol having a number average molecular weight of about 20,000.

Assignees

• Incept Llc

Inventors

• Jarrett Peter
• El-Hayek Rami
• Jarrett Timothy S
• Blizzard Charles D
• Sawhney Amarpreet S

Classifications

• A61K31/404

  Indoles, e.g. pindolol · CPC title

• A61K31/44

  Non condensed pyridines; Hydrogenated derivatives thereof · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K31/56

  Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title

• A61K31/517

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title